SCHEMBL9107

SCHEMBL9107

CCc1oc2ccc(Br)cc2c(=O)c1-c1cccc(F)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRP O00591 12/20 0.56
GABRD O14764 12/20 0.56
GABRA1 P14867 12/20 0.56
GABRB1 P18505 12/20 0.56
GABRG2 P18507 12/20 0.56
GABRB3 P28472 12/20 0.56
GABRA5 P31644 12/20 0.56
GABRA3 P34903 12/20 0.56
GABRA2 P47869 12/20 0.56
GABRB2 P47870 12/20 0.56
GABRA4 P48169 12/20 0.56
GABRE P78334 12/20 0.56
GABRA6 Q16445 12/20 0.56
GABRG1 Q8N1C3 12/20 0.56
GABRG3 Q99928 12/20 0.56
GABRQ Q9UN88 12/20 0.56
MAPT P10636 2/20 0.42
TP53 P04637 1/20 0.42
CYP3A4 P08684 1/20 0.42
MAPK1 P28482 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8856 0.91 GABRA1 (0.53) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL8632 0.91 GABRP (0.54) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL8941 0.88 GABRP (0.54) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL8459 0.86 GABRP (0.51) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL9741 0.85 GABRP (0.52) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL8910 0.82 TNKS (0.52) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL9273 0.81 GABRP (0.53) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL25808453 0.81 GABRP (0.51) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL8679 0.80 GABRP (0.55) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL8932 0.79 GABRP (0.51) GABRPGABRDGABRA1GABRB1GABRG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200239427-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2020-07-30 US claimed
EP-3444242-A2 NOVEL BENZOPYRAN KINASE MODULATORS Rhizen Pharmaceuticals S.A. (CH) 2019-02-20 EP claimed
EP-3050876-A2 KINASE MODULATORS Rhizen Pharmaceuticals S.A. (CH) 2016-08-03 EP claimed
EP-2496567-A2 NOVEL BENZOPYRAN KINASE MODULATORS Rhizen Pharmaceuticals S.A. (CH) 2012-09-12 EP claimed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 US claimed
WO-2011055215-A2 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2011-05-12 WO claimed
US-20240360095-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2024-10-31 US disclosed
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 US disclosed
US-20200239427-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2020-07-30 US disclosed
US-10442783-B2 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2019-10-15 US disclosed
EP-3444242-A2 NOVEL BENZOPYRAN KINASE MODULATORS Rhizen Pharmaceuticals S.A. (CH) 2019-02-20 EP disclosed
EP-2496567-B1 NOVEL BENZOPYRAN KINASE MODULATORS RHIZEN PHARMACEUTICALS S A (CH) 2017-07-12 EP disclosed
US-20160318890-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2016-11-03 US disclosed
US-9018375-B2 Substituted chromenes as kinase modulators RHIZEN PHARMACEUTICALS SA (CH) 2015-04-28 US disclosed
US-20140080827-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2014-03-20 US disclosed
US-8642607-B2 4H-chromen-4-one compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2014-02-04 US disclosed
EP-2496567-A2 NOVEL BENZOPYRAN KINASE MODULATORS Rhizen Pharmaceuticals S.A. (CH) 2012-09-12 EP disclosed
US-20120059001-A1 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2012-03-08 US disclosed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 US disclosed
WO-2011055215-A2 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2011-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10442783-B2 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases PIK3CB, PIK3CD, PDPK1 GABRP 1434/4885GABRD 2656/4885GABRA1 2758/4885
US-20240360095-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB GABRP 1342/4885GABRD 2739/4885GABRA1 3106/4885
US-20140080827-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB GABRP 1342/4885GABRD 2739/4885GABRA1 3106/4885
US-20110118257-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB GABRP 1342/4885GABRD 2739/4885GABRA1 3106/4885
US-20200239427-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB GABRP 1342/4885GABRD 2739/4885GABRA1 3106/4885
US-11858907-B2 Kinase modulators RPS6KA1, RPS6KA2, PRKAR2A GABRP 2530/4885GABRD 4049/4885GABRA1 3473/4885
US-20160318890-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB GABRP 1342/4885GABRD 2739/4885GABRA1 3106/4885
US-20120059001-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB GABRP 1342/4885GABRD 2739/4885GABRA1 3106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.